UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1664-1670

2008

Volltextzugriff (PDF)

Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group

Journal of clinical oncology, 2006-07, Vol.24 (21), p.3394-3400

2006

Volltextzugriff (PDF)

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma

Leukemia & lymphoma, 2014-02, Vol.55 (2), p.425-434

2014

Volltextzugriff (PDF)

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer

Breast cancer research and treatment, 2013-06, Vol.139 (2), p.553-560

2013

Volltextzugriff (PDF)

Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes

Journal of clinical oncology, 2002-06, Vol.20 (12), p.2805-2811

2002

Volltextzugriff (PDF)

Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients

Journal of clinical oncology, 2003-06, Vol.21 (11), p.2147-2155

2003

Volltextzugriff (PDF)

Expression of Receptor Activator of Nuclear Factor κB Ligand on Bone Marrow Plasma Cells Correlates with Osteolytic Bone Disease in Patients with Multiple Myeloma

Clinical cancer research, 2003-04, Vol.9 (4), p.1436

2003

Volltextzugriff (PDF)

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

Biochemical and biophysical research communications, 2005-07, Vol.333 (1), p.200-205

2005

Volltextzugriff (PDF)

Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE Study

Journal of clinical oncology, 2007-06, Vol.25 (18), p.2509-2515

2007

Volltextzugriff (PDF)

Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor α/γ, in human breast cancer cells

Molecular cancer therapeutics, 2009-08, Vol.8 (8), p.2296-2307

2009

Volltextzugriff (PDF)

Human bone marrow myeloma cells express RANKL

Journal of clinical oncology, 2002-01, Vol.20 (1), p.353-354

2002

Volltextzugriff (PDF)

Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial

Journal of clinical oncology, 2005-01, Vol.23 (3), p.432-440

2005

Volltextzugriff (PDF)

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

European journal of haematology, 2001-02, Vol.66 (2), p.83-88

2001

Volltextzugriff (PDF)

Immunocytochemistry reveals RANKL expression of myeloma cells

Blood, 2002-06, Vol.99 (12), p.4646-4647

2002

Volltextzugriff (PDF)

Proteasome: an emerging target for cancer therapy

Anti-cancer drugs, 2005-06, Vol.16 (5), p.475-481

2005

Volltextzugriff (PDF)

Facharztwissen Hämatologie Onkologie

5th edition, 2020

Volltextzugriff (PDF)

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

Annals of oncology, 2009-08, Vol.20 (8), p.1319-1329

2009

Volltextzugriff (PDF)

Serum Levels of Carboxy-terminal Telopeptide of Type-I Collagen Are Elevated in Patients with Multiple Myeloma Showing Skeletal Manifestations in Magnetic Resonance Imaging but Lacking Lytic Bone Lesions in Conventional Radiography

Clinical cancer research, 2003-08, Vol.9 (8), p.3047-3051

2003

Volltextzugriff (PDF)

Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1

Cancer letters, 2013-10, Vol.339 (2), p.288-297

2013

Volltextzugriff (PDF)

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

Journal of cancer research and clinical oncology, 2003-07, Vol.129 (7), p.383-391

2003

Volltextzugriff (PDF)

Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells

Anticancer research, 2018-05, Vol.38 (5), p.2669-2682

2018

Volltextzugriff (PDF)

Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

Annals of oncology, 2005-10, Vol.16 (10), p.1569-1583

2005

Volltextzugriff (PDF)

Nuclear matrix proteins as biomarkers for breast cancer

Expert review of molecular diagnostics, 2002-01, Vol.2 (1), p.23-31

2002

Volltextzugriff (PDF)

Metformin and the mTOR Inhibitor Everolimus (RAD001) Sensitize Breast Cancer Cells to the Cytotoxic Effect of Chemotherapeutic Drugs In Vitro

Anticancer research, 2012-05, Vol.32 (5), p.1627-1637

2012

Volltextzugriff (PDF)

1 – 25 von 348

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(235)

Publikationsform

Buchkapitel
(192)
Artikel
(151)
Bücher
(4)
Berichte
(1)

Sprache

Englisch
(250)
Deutsch
(98)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer

Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes

13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013)

Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients

Expression of Receptor Activator of Nuclear Factor κB Ligand on Bone Marrow Plasma Cells Correlates with Osteolytic Bone Disease in Patients with Multiple Myeloma

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE Study

Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor α/γ, in human breast cancer cells

Human bone marrow myeloma cells express RANKL

Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

Immunocytochemistry reveals RANKL expression of myeloma cells

Proteasome: an emerging target for cancer therapy

Facharztwissen Hämatologie Onkologie

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

Serum Levels of Carboxy-terminal Telopeptide of Type-I Collagen Are Elevated in Patients with Multiple Myeloma Showing Skeletal Manifestations in Magnetic Resonance Imaging but Lacking Lytic Bone Lesions in Conventional Radiography

Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells

Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

Nuclear matrix proteins as biomarkers for breast cancer

Metformin and the mTOR Inhibitor Everolimus (RAD001) Sensitize Breast Cancer Cells to the Cytotoxic Effect of Chemotherapeutic Drugs In Vitro

Suchergebnisse filtern